Table 1.
Clinical development of atypical antipsychotic drugs.
| Drug | Company | Year | Launch |
|---|---|---|---|
| Clozapine | Wander Laboratories | 1972 a | Switzerland |
| Zotepine | Fujisawa | 1982 b | Japan |
| Amisulpride | Synthelabo | 1986 | Portugal |
| Risperidone | Johnson & Johnson | 1993 | UK/Canada |
| Sertindole | Abbott Laboratories | 1996 c | UK |
| Olanzapine | Eli Lilly | 1996 | USA/UK |
| Quetiapine | AstraZeneca | 1997 | USA/UK |
| Ziprasidone | Pfizer | 2001 | USA |
| Perospirone | Dainippon Sumitomo Pharma | 2001 | Japan |
| Aripiprazole | Otsuka/Bristol-Myers Squibb | 2002 | USA |
| Paliperidone | Janssen Pharmaceutica | 2007 | USA |
| Blonanserin | Dainippon Sumitomo Pharma | 2008 | Japan |
| Asenapine | Schering-Plough | 2009 | USA |
| Iloperidone | Novartis AG | 2009 | USA |
| Lurasidone | Dainippon Sumitomo Pharma | 2011 | USA |
a Reintroduced in 1990 in USA and UK after being withdrawn from the market in 1975; b Commercialized by Astellas in Germany in 1990; c Marketing authorization was suspended by the European Medicines Agency (EMA) in 1998 and the drug was withdrawn from the market. In 2002, based on new data, the EMA suggested that sertindole could be reintroduced for restricted use, and with extensive ECG monitoring requirement.